{"id":25104,"date":"2025-11-03T10:51:28","date_gmt":"2025-11-03T15:51:28","guid":{"rendered":"https:\/\/medicarereport.org\/?p=25104"},"modified":"2025-11-03T10:51:32","modified_gmt":"2025-11-03T15:51:32","slug":"fda-moves-to-accelerate-biosimilar-development-and-lower-drug-costs","status":"publish","type":"post","link":"https:\/\/medicarereport.org\/?p=25104","title":{"rendered":"FDA Moves to Accelerate Biosimilar Development and Lower Drug Costs"},"content":{"rendered":"\n<p>(Source &#8211; www.hhs.gov)<\/p>\n\n\n\n<p>WASHINGTON\u2014 OCTOBER 29, 2025 \u2014 The U.S. Food and Drug Administration (FDA) today announced significant action to make it faster and less costly to develop biosimilar medicines, which are lower-cost \u201cgeneric\u201d alternatives to biologic drugs that treat serious and chronic diseases.  Continue reading <a href=\"https:\/\/www.hhs.gov\/press-room\/fda-accelerates-biosimilar-development-and-lowers-drug-costs.html\" data-type=\"link\" data-id=\"https:\/\/www.hhs.gov\/press-room\/fda-accelerates-biosimilar-development-and-lowers-drug-costs.html\">here&#8230;<\/a><\/p>\n\n\n\n<p><img loading=\"lazy\" decoding=\"async\" width=\"150\" height=\"101\" class=\"wp-image-8242\" style=\"width: 150px;\" src=\"https:\/\/medicarereport.org\/wp-content\/uploads\/2017\/09\/HHS-seal.jpg\" alt=\"\" srcset=\"https:\/\/medicarereport.org\/wp-content\/uploads\/2017\/09\/HHS-seal.jpg 339w, https:\/\/medicarereport.org\/wp-content\/uploads\/2017\/09\/HHS-seal-300x203.jpg 300w\" sizes=\"auto, (max-width: 150px) 100vw, 150px\" \/><\/p>\n\n\n\n<p class=\"has-small-font-size\"><strong>Notice:<\/strong>\u00a0The link provided above connects readers to the full content of the posted article. The URL (internet address) for this link is valid on the posted date; medicarereport.org cannot guarantee the duration of the link\u2019s validity. Also, the opinions expressed in these postings are the viewpoints of the original source and are not explicitly endorsed by AMAC, Inc.; the AMAC Foundation, Inc.; or medicarereport.org.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>(Source &#8211; www.hhs.gov) WASHINGTON\u2014 OCTOBER 29, 2025 \u2014 The U.S. Food and Drug Administration (FDA) today announced significant action to<\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[31,53,15],"tags":[428,76,385,238,261],"class_list":["post-25104","post","type-post","status-publish","format-standard","hentry","category-fda","category-hhs","category-part-dprescription-drugs","tag-biosimilars-drugs","tag-fda","tag-healthcare-costs","tag-healthcare-finance","tag-hhs"],"_links":{"self":[{"href":"https:\/\/medicarereport.org\/index.php?rest_route=\/wp\/v2\/posts\/25104","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/medicarereport.org\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/medicarereport.org\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/medicarereport.org\/index.php?rest_route=\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/medicarereport.org\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=25104"}],"version-history":[{"count":1,"href":"https:\/\/medicarereport.org\/index.php?rest_route=\/wp\/v2\/posts\/25104\/revisions"}],"predecessor-version":[{"id":25105,"href":"https:\/\/medicarereport.org\/index.php?rest_route=\/wp\/v2\/posts\/25104\/revisions\/25105"}],"wp:attachment":[{"href":"https:\/\/medicarereport.org\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=25104"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/medicarereport.org\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=25104"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/medicarereport.org\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=25104"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}